Protein StructureSGS Life Science Services, the leading pharmaceutical analytical and bioanalytical contract solutions provider, has announced the completion of an investment at its facility in West Chester (Pennsylvania, USA). Multiple new instruments for advanced analytical techniques have been installed and validated to support clients in the structural analysis of proteins

The West Chester facility has traditionally offered primary protein and glycosylation structural analysis, in addition to Circular Dichroism, used to determine secondary protein structure. This latest investment includes Analytical Ultra Centriguation (AUC) for determining protein aggregation, Size Exclusion Chromatography with Multi-Angle Laser Light Scattering for establishing molecular weight profiles, and Fourier transform infrared spectroscopy (FTIR) to examine protein secondary structure. These new services complement the existing services and provide a comprehensive and orthogonal approach to biotherapeutic protein analyses.

The facility now mirrors the company’s capabilities at its site in Wokingham, UK, which has built a reputation for offering world-class protein analysis to its clients in multiple areas. These include investigation of lot-to-lot variations, biosimilar comparability and shipment excursion studies to monitor the stability and sensitivity of biological molecules under various storage conditions.

“This investment will allow SGS to keep up with our clients’ ever growing pipelines for biological therapeutics, and also for the numerous biosimilars under development,” commented Mark Rogers, Senior VP, Life Science Services, SGS North America. “We have seen the demand for these services increase and, with the impending changes to legislation for marketing biosimilars, we envisage that the need for these analyses, to demonstrate similarity, will continue to grow.”

The investment comes after SGS last year announced increased analytical capabilities at its facilities across its global network in France, China, UK, India and the United States. With 19 laboratories offering contract analytical and bioanalytical services, SGS leverages its wholly owned global network, present in North America, Europe and Asia, to deliver harmonized solutions to large pharmaceutical and biotechnology firms. In addition to testing services for the bio/pharmaceutical market, SGS also provides Phase I to IV clinical trial management and services encompassing data management and statistics, PK/PD modeling and simulation, pharmacovigilance and regulatory consultancy.